We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Antisoma | LSE:ASM | London | Ordinary Share | GB0055696032 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.325 | 0.00 | 00:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 1.325 | GBX |
Antisoma (ASM) Share Charts1 Year Antisoma Chart |
|
1 Month Antisoma Chart |
Intraday Antisoma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 02/3/2016 | 10:00 | Interim Results | 1 |
| 25/2/2016 | 14:39 | Royal flush | 2 |
| 27/5/2015 | 11:41 | Only worth 17p on fundamentals | 7 |
| 07/6/2014 | 15:25 | Antisoma Cancer buster going to 50p ? | 5,775 |
| 14/9/2009 | 09:27 | antisoma - research shop | 14 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 31/10/2013 09:40 by minho What a sorry state of affairs. 2006 -2007 went from 12 p to 60p on possible good medical results. Antisoma tried real hard to crack the cancer blight, real pity it failed. At least they really had a good go at it. OXB 5p to 50p same,wife of ceo sold her total holding at 54p after that I never went back in. There is a huge failure list but I did believe in the possible good outcome of quite a few of these research stocks, as like so many of us we have lost loved ones to this terrible disease We live in hope. ASM might just develop a game changer yet. |
Posted at 20/12/2012 19:14 by leedskier 20 December 2012Antisoma plc ("Antisoma") Agreement with GVC Holdings plc ("GVC") The Directors announce that on 20 December 2012, Antisoma entered into an agreement to subscribe, as described below, up to GBP4.0 million of new ordinary shares proposed to be issued by GVC in connection with its recommended offer, together with William Hill Australia Pty Limited ("William Hill"), for Sportingbet plc ("Sportingbet") (the "Offer"), which was announced today. GVC has offered as consideration, for the businesses of Sportingbet which it proposes to acquire and retain, 29.0 million new GVC ordinary shares with a value of approximately GBP67.7 million at 233.5p per share, being the closing price on 15 October 2012, the last business day prior to the suspension of trading in GVC shares. Sportingbet shareholders are also being offered cash financed through a payment by William Hill in relation to the businesses of Sportingbet to be transferred to William Hill. As part of the GVC shares consideration, Sportingbet shareholders are being offered the opportunity to accept either these new GVC ordinary shares or a cash alternative of 233.5p per share. To the extent that a mix and match arrangement does not operate so as to deliver to any eligible Sportingbet shareholders the full amount of cash consideration for which they have elected, GVC has entered into a series of agreements whereby various parties have agreed to subscribe new GVC ordinary shares to underpin the cash consideration elected for by Sportingbet shareholders. Antisoma has entered into such an agreement with GVC to subscribe up to 1,713,062 new GVC ordinary shares at 233.5p per share, which represents a total potential commitment of GBP4.0 million. 1,713,062 new GVC ordinary shares would represent approximately 2.8 per cent. of GVC's issued ordinary share capital assuming full acceptance of the Offer. As consideration for this commitment, Antisoma has been granted subscription options over a further 343,053 new GVC ordinary shares, which are exercisable at 233.5p per share until the third anniversary from the date of grant. Antisoma's commitment continues until the earlier of the date on which the Offer is declared wholly unconditional or 30 June 2013. Antisoma will make a further announcement as soon as possible thereafter as to the number of new GVC ordinary shares subscribed under this agreement. In the 6 months ended 30 June 2012, GVC made a profit before taxation of Euro 5.2 million on revenue of Euro 29.1 million (Year ended 31 December 2011, loss before tax of Euro 0.14 million on revenue of Euro 44.34 million). Its net assets at 30 June 2012 amounted to Euro 57.98 million. Further information on the Offer, GVC and Sportingbet is set out in the announcement of the Offer of today's date. Contacts: Antisoma plc |
Posted at 11/7/2012 19:57 by jsbach123 There are convincing arguments that when a company clearly has failed but still has some assets to wind it up and return whatever value there is left to shareholders. Or if that is too complex and majority shraeholders are desperate to keep it trading perhaps ASM should reinvent itself as a tracker fund - more profitable probably johnsmith than the 'range of smaller investments' you envisage. |
Posted at 19/6/2012 14:59 by volsung 50p would be a nice price now. Another failed pharma to join the legion. |
Posted at 28/5/2012 21:19 by jsbach123 Another month passes with no news - though today has been 'enlivened' by a further slump in share price |
Posted at 26/10/2011 13:58 by fillipe My guess is that the move to the AIM will coincide with a merger or suchlike with one of ORA's other investments.I've had ASM in the past and done ok with them....have just taken 75k shrs which doesn't show up on either Level 2 or Plus, on the strength of eventually something worthwhile coming up as a result of the ORA holding. gla f |
Posted at 03/5/2011 12:04 by cumnor I think in two or three years we will see a very different ASM with a totally new business and share price multiples of what it is now, still a plc. The fact they did'nt just go for an all cash deal for some of the ip, retaining possibility of royalties and the interest which will have real resale value as and when the product is progressed, suggests to me they have a definite goal and we should start to see newsflow soon as the formalities of winding down the old ASM and reinvesting remaining cash unfold. imo dyor |
Posted at 28/4/2011 08:10 by cumnor Good news I feel. Suggests intention to remain listed but with completely different focus, possibly having taken on some private co like o/g or minerals explo and with significant cash reserves and backing of respected aggresive equity partners this could be due rerating thereafter. Also possibility of decent royalty returns (that is all it could ever have expected and not much less than normL) on it's total antibody ip which will cost nothing and be developed by larger pharma with clout to get anything out of it if it is going to succeed. I am happy to see it with smaller sale price but potential for decent returns long term if it's drugs turn up trumps as keeps investors interested and adds value at each stage if it passes trials. All speculation but i don't think ORA will be happy with anything less than 30p exit at some stage. Cash reserves important but backing of respected large investors and listing could take this anywhere. Certainly things happening as we hoped. Could we see renewed asm with much higher share price in a year or two. I think so. aimo dyor |
Posted at 03/2/2011 08:47 by wilba PWhite73I agree with your rationale. Please note: I believe the share movements were happening for months around the 6p mark. Me and Freddie Ferret made several observations and stated them on ther board. I agree that someone is aquiring and to be doing that must have had prior knowledge to the last RNS content.(Crystal balls). They will be in control of the share price and much to my disgust i expect the price to oscillate around this area for the interim whilst they take shares from weak holders. The only thing on your side is the time pressure of cash burn. So whatever they are up to they will have to do sooner than later. This is a double your money against lose most of it punt. If you held ASM you may have emotional attachment. If your new to it then your evaluation will at least be made on current fundamentals. Expect the unexpected. The next results may not be what you expect. Best of luck and good hunting. Regards. W. |
Posted at 26/4/2010 10:21 by bones698 in june asm will recieve £19.6m from the divesteture of a previous product. this will be shown in the resulst for june 30th :)what i am interested in seeing is how agressively they reduce the cash burn as its way over the top at present for such a small company. this needs to be reduced to aroound $10m for 6 months quickly. will be interesting to see what route asm now takes with the buisness. i suspect they will slim down significantly until the results of the as1413 trials are complete and a result known. two new institutions holding 9% between them have come onboard since the share price crash which should add confidence to the share price and whilst i see it hovering around this level until asm make some statements on whats happening i see a good chance of recovery. a boring few months to come but after that things should start to change, bidders may approach now they are vulnerable and i expect to see the share price pickup on award of the 19.6m being paid along with cost reductions |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
